» Articles » PMID: 20864054

Management of Patients with Myoclonus: Available Therapies and the Need for an Evidence-based Approach

Overview
Journal Lancet Neurol
Specialty Neurology
Date 2010 Sep 25
PMID 20864054
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Myoclonus is a hyperkinetic movement disorder characterised by quick and involuntary jerks. Therapy should focus on cure of an underlying disorder; however, symptomatic treatment is often needed when treatment of an underlying cause is impossible or ineffective. The appropriate treatment for a specific type of myoclonus is based on the classification of the anatomical origin of the myoclonus: cortical, subcortical, spinal, or peripheral. We outline criteria for classification and present an overview of the available therapeutic options for the different types of myoclonus. Because of a generally low level of evidence, therapeutic options mainly rely on small observational studies and expert opinion. For an evidence-based approach in the future, randomised controlled trials of symptomatic therapies for myoclonus in homogeneous patient groups are needed.

Citing Articles

Drug-Induced Myoclonus: A Systematic Review.

Rissardo J, Caprara A, Bhal N, Repudi R, Zlatin L, Walker I Medicina (Kaunas). 2025; 61(1).

PMID: 39859113 PMC: 11767161. DOI: 10.3390/medicina61010131.


Myoclonus: Differential diagnosis and current management.

Riva A, DOnofrio G, Ferlazzo E, Pascarella A, Pasini E, Franceschetti S Epilepsia Open. 2024; 9(2):486-500.

PMID: 38334331 PMC: 10984309. DOI: 10.1002/epi4.12917.


Myoclonus and other jerky movement disorders.

van der Veen S, Caviness J, Dreissen Y, Ganos C, Ibrahim A, Koelman J Clin Neurophysiol Pract. 2022; 7:285-316.

PMID: 36324989 PMC: 9619152. DOI: 10.1016/j.cnp.2022.09.003.


Antiseizure Drugs and Movement Disorders.

Saenz-Farret M, Tijssen M, Eliashiv D, Fisher R, Sethi K, Fasano A CNS Drugs. 2022; 36(8):859-876.

PMID: 35861924 DOI: 10.1007/s40263-022-00937-x.


Cortical myoclonic tremor after chimeric antigen receptor T-cell therapy.

Swinnen B, van Rootselaar A, Spanjaart A, de Bie R, Kersten M, van de Beek D J Neurol. 2022; 269(9):5165-5169.

PMID: 35403878 DOI: 10.1007/s00415-022-11127-6.